CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Head & Neck Cancers
Immunotherapy in GU Cancers
Immunotherapy in Lung Cancer
Immunotherapy in Melanoma
Mantle Cell Lymphoma
Melanoma & Skin Cancer
Metastatic Castration-Resistant Prostate Cancer
Oncology Nursing News
Precision Medicine in Oncology
Special Reports in Personalized Cancer Care
SELECT A TOPIC
VISITING CHICAGO? JOIN US IN RECOGNIZING OUR 2018 GIANTS OF CANCER CARE® ON MAY 31st AND VISIT BOOTH 2073 JUNE 2nd-4th!
<< View More Conferences
2017 SITC Meeting
Oncology Conference Multimedia
View more videos >>
Dr. Hong Discusses IPI-549 in Advanced Solid Tumors
Dr. Paulson Discusses Acquired Resistance to Immunotherapy
Dr. Luke on Combining an IDO Inhibitor With Nivolumab in Advanced Cancers
Oncology Conference Articles
Novel Combination Shows Promising Responses in Pancreatic Cancer
The combination of cabiralizumab and nivolumab resulted in intriguing objective response rates in heavily pretreated patients with metastatic pancreatic cancer.
Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma
Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.
NKTR-214/Nivolumab Combination Shows Promise in Early Study
The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.
IDO Plus PD-1 Inhibitor Combo Sparks Responses in Bladder and Cervical Cancers
The combination of nivolumab and BMS-986205 generated promising response rates without increasing adverse effects in patients with advanced cervical or bladder cancers.
Nivolumab Spurs Responses in non-CRC Patients With dMMR
Nivolumab demonstrated a 24% overall response rate among patients with a range of non-colorectal cancers with mismatch repair deficiency who were identified through the NCI-MATCH trial.
JCAR015 Experience Informs Future CAR-T Studies
The high rates of cerebral edema seen with JCAR015 in the phase II ROCKET trial were attributed to early and rapid chimeric antigen receptor (CAR)-modified T-cell expansion and a rise in interleukin-15 levels, a finding that could help inform future CAR T-cell usage.
Combinations Required to Further Advance Adoptive T-Cell Therapy
A variety of adoptive T-cell therapy strategies have shown promise in clinical studies with recent FDA approvals granted to CAR-modified T-cell therapies, representing the potential for future combination strategies.
CAR T-Cell Therapy in DLBCL: Centers of Excellence
Study Identifies Factors Linked to Long-Term Survival in Pediatric/Adolescent DIPG
Harvard Expert Sees Potential in BCL-2 Combos
Tocilizumab Resolves CRS in Pediatric B-ALL Without Reducing Tisagenlecleucel Efficacy
Bounty of Novel Drugs Ushers In New Era for ALK-Positive NSCLC
Covering Every Angle of Oncology Practice. Click a cover below, to view more.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
2 Clarke Drive
Cranbury, NJ 08512
Copyright OncLive 2006-2018
Intellisphere, LLC. All Rights Reserved.